tiprankstipranks
Analyst Profile
Followed by 4 other investors
.
Sebastien Malafosse

Sebastien Malafosse

Oddo BHF
Wall Street Analyst
Ranked #6,011 out of 8,047 Analysts on TipRanks (#15,860 out of 21,521 overall experts)

Success Rate

33%
2 out of 6 Profitable Transactions

Average Return

-5.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Sebastien Malafosse's ratings since 2020 and opened each position for the duration of 1 Year:
33.33% of your transactions would have been profitable with an average return of -5.5%

Stock Rating Distribution

7Ratings
57.14% Sell
28.57% Buy
14.29% Hold
Distribution of Sebastien Malafosse's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
AstraZeneca plc
(AZN)
Rating Type:Buy
Dates:Sep 23, 2020 - Sep 23, 2021
Gain:1.10%
The most profitable rating made by Sebastien Malafosse

Sebastien Malafosse's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
AstraZeneca
Sep 23, 2020
Buy
Upgraded
10,200.00p
(-4.92% Downside)
50%
-2.65%
2
GlaxoSmithKline
Sep 23, 2020
Buy
Upgraded
1,810.00p
(24.67% Upside)
100%
+0.30%
1
Novartis
Sep 23, 2020
Hold
Downgraded
$98.77
(15.28% Upside)
0.00%
1
Roche Holding AG
Feb 04, 2021
Sell
Reiterated
$307.99
(-4.82% Downside)
0%
-9.50%
3
List of latest recommendations made by Sebastien Malafosse. Click to expand and see Sebastien Malafosse's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More